ARTICLE | Product Development
Synthetic lethality, protein degradation programs disappoint at AACR
C4, Zentalis and Repare are among the companies falling on AACR22 data
April 9, 2022 1:15 AM UTC
It was a rough day at the American Association for Cancer Research annual meeting for two of the most promising therapeutic classes: synthetic lethality and targeted degraders.
On Friday, shares of targeted degradation company C4 Therapeutics Inc. (NASDAQ:CCCC) fell $11.58 (51%) to $11.32 on new data from its IKZF1/IKZF3 degrader...
BCIQ Target Profiles